Sector Expert: Neil Maruoka

Canaccord Genuity



Recent Quotes

"HLTH has indicated that it continues to pursue additional accretive acquisitions."

— Neil Maruoka, Canaccord Genuity (8/2/16)
more >

"We are initiating coverage of HLTH with a Buy rating;we see upside to our valuation with further Athas-generated organic growth, and future accretive acquisitions of surgical facilities."

— Neil Maruoka, Canaccord Genuity (7/13/16)
more >

"ONCY's phase 3 study results should be a major milestone for the stock."

— Neil Maruoka, Canaccord Genuity (10/2/13)
more >

"ONCY reported positive response rate data from its phase 2 study of Reolysin."

— Neil Maruoka, Canaccord Genuity (9/9/13)
more >

"ONCY's burn rate has dropped substantially, and it has adequate cash on hand."

— Neil Maruoka, Canaccord Genuity (8/1/13)
more >

"Based on recent evidence of efficacy for Reolysin, we would be buyers of ONC stock."

— Neil Maruoka, Canaccord Genuity (5/9/13)
more >

"We anticipate more impactful data from ONCY's Reolysin trial."

— Neil Maruoka, Canaccord Genuity (3/15/13)
more >

"ONCY's phase 2, Reolysin study results look to be exceptional."

— Neil Maruoka, Canaccord Genuity (2/8/13)
more >



Due to permission requirements, not all quotes are shown.